-
1
-
-
0000022264
-
Prevalence and natural history of diabetes in Trinidad
-
P oon-King T, Henry MU, Rampersad F. Prevalence and natural history of diabetes in Trinidad. Lancet 1969;i:155-160
-
(1969)
Lancet
, vol.1
, pp. 155-160
-
-
Oon-King T, P.1
Henry, M.U.2
Rampersad, F.3
-
2
-
-
0024855273
-
Ethnicity and other characteristics predicttive of coronary heart disease in a developing community: Principal results of the St James Survey, Trinidad
-
Miller GJ, Beckles GL, Maude GH et al. Ethnicity and other characteristics predictive of coronary heart disease in a developing community: principal results of the St James Survey, Trinidad. Int J Epidemiol 1989;18:808-817
-
(1989)
Int J Epidemiol
, vol.18
, pp. 808-817
-
-
Miller, G.J.1
Beckles, G.L.2
Maude, G.H.3
-
4
-
-
2442719098
-
Chronic diseases: The new epidemic
-
Wilks R, Bennett F, Forrester T, McFarlane-Anderson N. Chronic diseases: the new epidemic. West Indian Med J 1998;47(suppl 4):40-44
-
(1998)
West Indian Med J
, vol.47
, Issue.SUPPL. 4
, pp. 40-44
-
-
Wilks, R.1
Bennett, F.2
Forrester, T.3
McFarlane-Anderson, N.4
-
6
-
-
74549133218
-
Heart disease in Trinidad
-
Wattley GH. Heart disease in Trinidad. West Indian Med J 1960;9:189-193
-
(1960)
West Indian Med J
, vol.9
, pp. 189-193
-
-
Wattley, G.H.1
-
7
-
-
33747123968
-
Cardiovascular diseases in Latin America and the Caribbean
-
Barceló A. Cardiovascular diseases in Latin America and the Caribbean. Lancet 2006;368:625-626
-
(2006)
Lancet
, vol.368
, pp. 625-626
-
-
Barceló, A.1
-
9
-
-
31744432315
-
The metabolic syndrome and cardiovascular disease
-
Bonora E. The metabolic syndrome and cardiovascular disease. Ann Med 2006;38:64-80.
-
(2006)
Ann Med
, vol.38
, pp. 64-80
-
-
Bonora, E.1
-
10
-
-
22644438664
-
The sentinel practice network of the basque country. Socio-economic inequalities in the prevalence of type 2 diabetes, cardiovascular risk factors and chronic diabetic complications in the basque country, Spain.
-
Larrañaga I, Arteagoitia JM, Rodriguez JL et al. The Sentinel Practice Network of the Basque Country. Socio-economic inequalities in the prevalence of Type 2 diabetes, cardiovascular risk factors and chronic diabetic complications in the Basque Country, Spain. Diabet Med 2005;22:1047-1053
-
(2005)
Diabet Med
, vol.22
, pp. 1047-1053
-
-
Larrañaga, I.1
Arteagoitia, J.M.2
Rodriguez, J.L.3
-
12
-
-
74549157549
-
Metformin
-
Bailey CJ, Campbell IW, Chan JCN et al. (eds). Chichester: John Wiley &Sons Ltd
-
Bailey CJ, Campbell IW, Chan JCN et al. (eds). Metformin. The Gold Standard. Chichester: John Wiley &Sons Ltd, 2007;288.
-
(2007)
The Gold Standard
, vol.288
-
-
-
13
-
-
0035467671
-
Chronic diseases management in the Jamaican setting: HOPE worldwide Jamaica's experience
-
Swaby P, Wilson E, Swaby S et al. Chronic diseases management in the Jamaican setting: HOPE worldwide Jamaica's experience. P N G Med J 2001;44:171-175
-
(2001)
P N G Med J
, vol.44
, pp. 171-175
-
-
Swaby, P.1
Wilson, E.2
Swaby, S.3
-
14
-
-
17844376531
-
Changing patterns of primary care for diabetes in trinidad and tobago over 10 years
-
Mahabir D, Gulliford MC. Changing patterns of primary care for diabetes in Trinidad and Tobago over 10 years. Diabet Med 2005;22:619-624
-
(2005)
Diabet Med
, vol.22
, pp. 619-624
-
-
Mahabir, D.1
Gulliford, M.C.2
-
15
-
-
0032511566
-
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
-
UK Prospective Diabetes Study (UKPDS) Group
-
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:854-865
-
(1998)
Lancet
, vol.352
, pp. 854-865
-
-
-
16
-
-
0035883890
-
Metformin in non-alcoholic steatohepatitis
-
Marchesini G, Brizi M, Bianchi G et al. Metformin in non-alcoholic steatohepatitis. Lancet 2001;358:893-894
-
(2001)
Lancet
, vol.358
, pp. 893-894
-
-
Marchesini, G.1
Brizi, M.2
Bianchi, G.3
-
17
-
-
33747663672
-
Metformin treatment to prevent early puberty in girls with precocious pubarche
-
Ibáñez L, Ong K, Valls C et al. Metformin treatment to prevent early puberty in girls with precocious pubarche. J Clin Endocrinol Metab 2006;91:2888-2891
-
(2006)
J Clin Endocrinol Metab
, vol.91
, pp. 2888-2891
-
-
Ibáñez, L.1
Ong, K.2
Valls, C.3
-
18
-
-
0142247208
-
Metformin in polycystic ovary syndrome: Systematic review and meta-analysis
-
Lord JM, Flight IHK, Norman RJ. Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ 2003;327:951-953
-
(2003)
BMJ
, vol.327
, pp. 951-953
-
-
Lord, J.M.1
Flight, I.H.K.2
Norman, R.J.3
-
20
-
-
74549185490
-
Prevalence of diabetes mellitus among pregnant women receiving health services at the puerto rico university hospital
-
Puerto Rico, 1997-1998
-
Acosta I, Aponte Z, de-Jesús Z et al. Prevalence of diabetes mellitus among pregnant women receiving health services at the Puerto Rico University Hospital, Puerto Rico, 1997-1998. P R Health Sci J 2001;201:65-70.
-
(2001)
P R Health Sci J
, vol.201
, pp. 65-70
-
-
Acosta, I.1
Aponte, Z.2
De-Jesús, Z.3
-
21
-
-
42149100624
-
The burden of gestational diabetes mellitus in Jamaican women with a family history of autosomal dominant type 2 diabetes
-
Irving RR , Mills JL , Choo-Kang EG et al. The burden of gestational diabetes mellitus in Jamaican women with a family history of autosomal dominant type 2 diabetes. Rev Panam Salud Publica 2008;23:85-91.
-
(2008)
Rev Panam Salud Publica
, vol.23
, pp. 85-91
-
-
Irving, R.R.1
Mills, J.L.2
Choo-Kang, E.G.3
-
22
-
-
36049030622
-
Counterpoint: Oral hypoglyemic agents should be used to treat diabetic pregnant women
-
Coetzee EJ. Counterpoint: Oral hypoglyemic agents should be used to treat diabetic pregnant women. Diabetes Care 2007;30:2980-2982
-
(2007)
Diabetes Care
, vol.30
, pp. 2980-2982
-
-
Coetzee, E.J.1
-
23
-
-
43249092553
-
MiG Trial Investigators. Metformin versus insulin for the treatment of gestational diabetes
-
Rowan JA, Hague WM, Gao W et al. MiG Trial Investigators. Metformin versus insulin for the treatment of gestational diabetes. N Engl J Med 2008;358:2003-2015
-
(2008)
N Engl J Med
, vol.358
, pp. 2003-2015
-
-
Rowan, J.A.1
Hague, W.M.2
Gao, W.3
-
24
-
-
3042685726
-
Height, weight, and motorsocial development during the first 18 months of life in 126 infants born to 109 mothers with polycystic ovary syndrome who conceived on and continued metformin through pregnancy
-
Glueck CJ, Goldenberg N, Pranikoff J et al. Height, weight, and motorsocial development during the first 18 months of life in 126 infants born to 109 mothers with polycystic ovary syndrome who conceived on and continued metformin through pregnancy. Hum Reprod 2004;19:1323-1330
-
(2004)
Hum Reprod
, vol.19
, pp. 1323-1330
-
-
Glueck, C.J.1
Goldenberg, N.2
Pranikoff, J.3
-
25
-
-
33847722632
-
Metformin before and during pregnancy and lactation in polycystic ovary syndrome
-
Glueck CJ, Wang P. Metformin before and during pregnancy and lactation in polycystic ovary syndrome. Expert Opin Drug Saf 2007;6:191-198
-
(2007)
Expert Opin Drug Saf
, vol.6
, pp. 191-198
-
-
Glueck, C.J.1
Wang, P.2
-
26
-
-
0141724824
-
Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, d-chiro-inositol) for polycystic ovary syndrome
-
Lord JM, Flight IH, Norman RJ. Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, d-chiro-inositol) for polycystic ovary syndrome. Cochrane Database Syst Rev 2003;3:CD003053.
-
(2003)
Cochrane Database Syst Rev
, vol.3
-
-
Lord, J.M.1
Flight, I.H.2
Norman, R.J.3
-
27
-
-
28244449607
-
Insulin-sensitisers in the treatment of polycystic ovary syndrome
-
DOI 10.1517/14656566.6.14.2419
-
Teede HJ, Meyer C, Norman RJ . Insulin-sensitisers in the treatment of polycystic ovary syndrome. Expert Opin Pharmacother 2005;6: 2419-2427 (Pubitemid 41701044)
-
(2005)
Expert Opinion on Pharmacotherapy
, vol.6
, Issue.14
, pp. 2419-2427
-
-
Teede, H.J.1
Meyer, C.2
Norman, R.J.3
-
28
-
-
36549034292
-
Metformin improves polycystic ovary syndrome symptoms irrespective of pre-treatment insulin resistance
-
Tan S, Hahn S, Benson S et al. Metformin improves polycystic ovary syndrome symptoms irrespective of pre-treatment insulin resistance. Eur J Endocrinol 2007;157:669-676
-
(2007)
Eur J Endocrinol
, vol.157
, pp. 669-676
-
-
Tan, S.1
Hahn, S.2
Benson, S.3
-
29
-
-
34548729888
-
Clomiphene versus metformin for ovulation induction in polycystic ovary syndrome: The winner is...
-
Barbieri RL. Clomiphene versus metformin for ovulation induction in polycystic ovary syndrome: the winner is... J Clin Endocrinol Metab 2007;92:3399-3401
-
(2007)
J Clin Endocrinol Metab
, vol.92
, pp. 3399-3401
-
-
Barbieri, R.L.1
-
30
-
-
23044513823
-
Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome
-
Palomba S, Orio F Jr, Falbo A et al. Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005;90:4068-4074
-
(2005)
J Clin Endocrinol Metab
, vol.90
, pp. 4068-4074
-
-
Palomba, S.1
Orio Jr., F.2
Falbo, A.3
-
31
-
-
40349085776
-
Consensus on infertility treatment related to polycystic ovary syndrome
-
Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group
-
Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Consensus on infertility treatment related to polycystic ovary syndrome. Fertil Steril 2008;89:505-522
-
(2008)
Fertil Steril
, vol.89
, pp. 505-522
-
-
-
32
-
-
18744381558
-
American association of clinical endocrinologists position statement on metabolic and cardiovascular consequences of polycystic ovary syndrome
-
Polycystic Ovary Syndrome Writing Committee. American Association of Clinical Endocrinologists position statement on metabolic and cardiovascular consequences of polycystic ovary syndrome
-
Polycystic Ovary Syndrome Writing Committee. American Association of Clinical Endocrinologists position statement on metabolic and cardiovascular consequences of polycystic ovary syndrome. American Association of Clinical Endocrinologists position statement on metabolic and cardiovascular consequences of polycystic ovary syndrome. Endocr Pract 2005;11:125-134
-
(2005)
Endocr Pract
, vol.11
, pp. 125-134
-
-
|